TAC’s media and corporate affairs manager, Nicholas McGay, told AdNews the tender process followed two stages, an open market ...

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) today announced the latest results from the ongoing Phase I/II CLINCH ...

New York, USA, October 20th, 2025, FinanceWire Vesalius Longevity Labs, the first soon-to-be publicly traded company ...

Dr. Greg Hundley: Yes, Peder, let's go. Dr. Peder Myhre: ...

REE Project SAN BERNARDINO, CA / ACCESS Newswire / October 20, 2025 / Dateline Resources Limited (ASX:DTR)(OTCQB:DTREF)(FSE:YE1) (Dateline or the Company) is pleased to announce the completion of an ...

President Lee Jae-myung said in a congratulatory speech at the opening ceremony of ‘ADEX 2025’, South Korea’s largest defense ...

Telisotuzumab adizutecan shows promising antitumor activity in advanced pancreatic cancer, with manageable safety and significant clinical benefits in a phase 1 study.

Third synthetic royalty transaction & second pre-approval deal for DRI – – Further increases portfolio exposure to rare diseases – – Long-dated cashflows, extend portfolio duration – – DRI ...

In a Phase III trial, sacituzumab tirumotecan outperformed chemo in previously treated EGFR-mutant NSCLC patients, results presented at the ESMO Congress show.

Master income statement analysis—discover its components, read financial health indicators, and make informed financial decisions. Your guide to assessing business performance.